Press-release for stocks publishing date 2021 - 12

Prices are updated after-hours

publishing date : 2021 - 12 - 20 tags : Therapeutics

save search

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
CTMX | $1.68 0.6% 0.6% 290K

Health Technology

| -74.11% | O: -21.71% H: 0.29% C: -23.37%
cx-2029 phase 2 ongoing expansion drug therapeutics results antibody

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
CORT | News | $23.0 3.14% 3.04% 1.9M

Health Technology

| 7.21% | O: 0.96% H: 0.0% C: -2.19%
therapeutics results

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
Published: 2021-12-20 (Crawled : 17:00) - biospace.com/
ALRN | $4.95 4.21% 4.04% 68K

Health Technology

| 779.63% | O: -2.02% H: 3.95% C: -1.74%
urea therapeutics

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
CARA | $0.7097 -2.83% -2.92% 180K

Health Technology

| -94.14% | O: -0.6% H: 0.2% C: -1.34%
therapeutics injection granted grant

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
SRNE | $0.015 -8.85% 140K

Health Technology

| -99.84% | O: -1.46% H: 1.49% C: -2.34%
sti-1386 fda clearance solid tumors application therapeutics fda clearance

Turning Point Therapeutics Provides Regulatory Updates
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
TPTX | $76.01 -0.03%

Health Technology

| 69.66% | O: -7.33% H: 13.38% C: 10.88%
therapeutics

CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
Published: 2021-12-20 (Crawled : 15:30) - globenewswire.com
LVTX | $2.99 4.91% 4.68% 110K

| -46.23% | O: -1.89% H: 5.0% C: -1.92%
health thc conference therapeutics j.p. morgan healthcare conference

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
FNCH | $2.79 20.78% 17.2% 510K

Professional, Scientific, and T...

| -74.19% | O: -0.45% H: 11.11% C: 8.64%
therapeutics

Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
PTCT | News S | $25.38 -2.27% -2.32% 750K

Health Technology

| -33.6% | O: -0.59% H: 4.81% C: 3.55%
huntington therapeutics disease platform huntington’s disease

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
Published: 2021-12-20 (Crawled : 14:00) - biospace.com/
PSTX | $2.15 -0.23% -0.23% 420K

Health Technology

| -65.15% | O: 7.29% H: 8.01% C: 7.4%
new drug fda clearance solid tumors application car-t drug therapeutics fda clearance

Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
Published: 2021-12-20 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1691 -6.0% -6.39% 38M

Health Technology

| -83.18% | O: 2.8% H: 6.36% C: 4.55%
health drug therapeutics disease orphan drug rare

Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Published: 2021-12-20 (Crawled : 14:00) - biospace.com/
SMMT | $3.72 6.59% 6.18% 1.8M

Health Technology

| -24.3% | O: -39.48% H: 7.29% C: -7.17%
therapeutics topline results topline infection infections

Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
MITO | $0.32 0.25%

Health Technology

| -63.85% | O: -9.49% H: 11.47% C: 6.73%
muscular dystrophy therapeutics duchenne positive iot

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
LVTX | $2.99 4.91% 4.68% 110K

| -46.23% | O: -1.89% H: 5.0% C: -1.92%
health thc conference therapeutics j.p. morgan healthcare conference

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K

Health Care and Social Assistan...

| -30.52% | O: 0.1% H: 0.0% C: -3.4%
vrdn-001 eye eye disease trial therapeutics disease phase 1 phase 2

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
Published: 2021-12-20 (Crawled : 13:00) - biospace.com/
NTLA | $21.535 -1.35% -1.37% 850K

Health Technology

| -80.78% | O: 11.75% H: 0.07% C: -3.37%
therapeutics intel

Palantir and Dewpoint Therapeutics Announce Strategic Partnership
Published: 2021-12-20 (Crawled : 13:00) - biospace.com/
PLTR | $21.64 3.2% 0.42% 36M

Technology Services